Portal de Periódicos da CAPES

Primaquine radical cure in patients with Plasmodium falciparum malaria in areas co-endemic for P falciparum and Plasmodium vivax (PRIMA): a multicentre, open-label, superiority randomised controlled trial

2023; Elsevier BV; Volume: 402; Issue: 10417 Linguagem: Inglês

10.1016/s0140-6736(23)01553-2

1474-547X

Kamala Thriemer, Tamiru Shibiru Degaga, Michael Christian, Mohammad Shafiul Alam, Megha Rajasekhar, Benedikt Ley, Mohammad Sharif Hossain, Mohammad Golam Kibria, Tedla Teferi Tego, Dagamawie Tadesse Abate, Sophie Weston, Hellen Mnjala, Angela Rumaseb, Ari Winasti Satyagraha, Arkasha Sadhewa, Lydia Vista Panggalo, Lenny L. Ekawati, Grant Lee, Rodas Temesgen, Fitsum Getahun Kiros, J. A. Simpson, Amalia Karahalios, Adugna Woyessa, J. Kevin Baird, Inge Sutanto, Asrat Hailu, Ric N. Price,

Infectious Encephalopathies and Encephalitis

In areas co-endemic for Plasmodium vivax and Plasmodium falciparum there is an increased risk of P vivax parasitaemia following P falciparum malaria. Radical cure is currently only recommended for patients presenting with P vivax malaria. Expanding the indication for radical cure to patients presenting with P falciparum malaria could reduce their risk of subsequent P vivax parasitaemia.